Detection of BRAF mutations in CRC is of high importance due to clinical relevance regarding responsiveness to monoclonal antibody treatment that targets eGFR, a worse outcome in the presence of V600 mutations, and, in some situations, it facilitates the determination of whether the carcinoma is of somatic origin [6,15,16]. The gene discussed is BRAF; the disease is colorectal carcinoma.